Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.45 |
| ▸ | HTR2A | P28223 | 7/20 | 0.45 |
| ▸ | HTR2B | P41595 | 7/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638955 | 0.86 | HTR2C (0.44) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| SCHEMBL263979 | 0.79 | HTR2C (0.42) | HTR2CHTR2AHTR2BSLC6A2 | |
| Hydrochloric Acid SCHEMBL7249716 | 0.77 | HTR2C (0.41) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL10382642 | 0.77 | HTR2C (0.41) | HTR2CHTR2AHTR2B | |
| SCHEMBL17103038 | 0.77 | HTR2C (0.40) | HTR2CHTR2AHTR2BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL31738277 | 0.76 | MEN1 (0.42) | SLC6A4CHRNB2CHRNA4PDE10A | |
| SCHEMBL7997129 | 0.75 | HTR2A (0.36) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| SCHEMBL1638818 | 0.75 | HTR2A (0.45) | HTR2CHTR2AHTR2BSLC6A2SLC6A4 | |
| SCHEMBL263978 | 0.74 | HTR3A (0.53) | SLC6A2SLC6A4HTR3A | |
| SCHEMBL1673686 | 0.74 | HTR3A (0.53) | SLC6A2SLC6A4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492394-B2 | (3-aryl-piperazin-1-yl), (2-aryl-morpholin-4-yl) and (2-aryl-thiomorpholin-4-yl) derivatives of 6,7-dialkoxy-quinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2013-07-23 | — | — | US | disclosed |
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2057153-B1 | (3-ARYL-PIPERAZIN-1-YL) DERIVATIVES OF 6,7-DIALKOXYQUINAZOLINE, 6,7- DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE | LUNDBECK & CO AS H (DK) | 2012-09-12 | — | — | EP | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110098286-A1 | (3-ARYL-PIPERAZIN-1-YL), (2-ARYL-MORPHOLIN-4-YL) AND (2-ARYL-THIOMORPHOLIN-4-YL) DERIVATIVES OF 6,7-DIALKOXY-QUINAZOLINE, 6,7-DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE | H. LUNDBECK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
| EP-2057153-A1 | (3-ARYL-PIPERAZIN-1-YL), (2-ARYL-MORPHOLIN-4-YL) AND (2-ARYL- THIOMORPHOLIN-4-YL) DERIVATIVES OF 6,7-DIALKOXYQUINAZOLINE, 6,7- DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE | H.Lundbeck A/S (DK) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008006372-A1 | (3-ARYL-PIPERAZIN-1-YL), (2-ARYL-MORPHOLIN-4-YL) AND (2-ARYL- THIOMORPHOLIN-4-YL) DERIVATIVES OF 6,7-DIALKOXYQUINAZOLINE, 6,7- DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE | H. LUNDBECK A/S (DK) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098286-A1 | (3-ARYL-PIPERAZIN-1-YL), (2-ARYL-MORPHOLIN-4-YL) AND (2-ARYL-THIOMORPHOLIN-4-YL) DERIVATIVES OF 6,7-DIALKOXY-QUINAZOLINE, 6,7-DIALKOXYPHTALAZINE AND 6,7-DIALKOXYISOQUINOLINE | PDE5A, PDE2A, PDE3A | HTR2C 47/4885HTR2A 40/4885HTR2B 80/4885 |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | HTR2C 3581/4885HTR2A 3775/4885HTR2B 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.